We drive increased quality, yield and scalability from initial breakthroughs to market approval.
Gene Therapy at the edge of impossible
OXGENE offers a range of licensable viral technologies including AAV vectors, lentiviral vectors and adenoviral vectors as well as custom solutions to meet the manufacturing demands of new CAR-T and gene therapies. Our high titre, high-quality suspension transient viral manufacturing systems, inducible viral packaging and producer cell lines, and the world’s first contaminant-free adenovirus-based AAV production system all address the industry-wide challenge of scalability.
We bring better viral solutions to the clinical arena. And we’re doing it faster and more efficiently than ever before.
The simplicity and versatility of our SnapFast™ Plasmids makes genetic engineering more efficient than with standard tools.
This proprietary technology enables us to generate any number of custom constructs by the systematic and simple transfer of DNA building blocks across a range of expression platforms.
We also offer an extensive index of pre-validated plasmids, which we can use to perform genetic screens to increase viral titre and productivity.
HEK293 Suspension Cell Lines (GMP-compliant)
OXGENE’s licensable GMP-compliant, suspension, HEK293 cell lines produce recombinant AAV (rAAV), lentiviral and adenoviral vectors. Our customers report high growth rate, high titre and all-round excellent performance.
We offer these suspension HEK293 cell lines together with our optimized SnapFast™ plasmid systems. This cutting-edge solution for scalable transient gene therapy manufacture increases productivity for both rAAV and lentiviral vectors. We now have multiple partners using these solutions in their clinical development programs.
We aim to transition the gene therapy industry to new levels of scalability with the world’s first GMP-compliant, suspension mode, stable packaging and producer HEK293 cell lines.